Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q2 2019 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, 2019
Slide 1: Agilent Technologies Q2'19 Results Presentation
Agilent Technologies Q2'19 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth o
Slide 3: Agilent Results Q2'19
Agilent Results Q2'19 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q2'19 Financial Metrics Q2'19 Headlines • Revenues: $1.24B, +4.0% y/y core(1)(2),+2.7% • Growth: Solid growth in Environmental & reported (+1.9% M&A, -3.2% FX). Forensics and Chem & Energy mar
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Core revenue performance driven by ongoing Instrumentation and Informatics strength in the Chemical & Energy, Forensics & for Analytical Laboratories Environmental, and BioPharma markets offset by slowing global small molecule Pharma and softness in the
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Continued strong revenue performance across Analytical Laboratory Consumables and Services both services and consumables. Growth in all regions led by China. • Operating Margin in the quarter was 25.2%(1)(2), up 270 bps versus last year. • ACG grew in the mid-teens in
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Solid core revenue growth, in line with expectations, Pathology, Genomics, and was led by strength in the Americas, Pathology Nucleic Acid Manufacturing related businesses, and NASD. • Operating Margin for the quarter was 19.3%(1)(2), down 60 bps versus last ye
Slide 7: Growth in a $52B Market – Q2'19 Results by End Market
Growth in a $52B Market – Q2'19 Results by End Market Gains highlighted by solid Environmental/Forensics and Chemical/Energy Analytical Laboratory End Markets Q2'19 revenues: +4% y/y on core(2) basis Pharma & Biotech: Up 2% with strength in BioPharma, after-market Services and Consumables, and N
Slide 8: Q3'19 and FY19 Guidance and Forward-looking Considerations
Q3’19 and FY19 Guidance and Forward-looking Considerations Based on April 30, 2019 Exchange Rates Q3’19 Guidance (1) FY Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,225 $1,245 Net Revenue ($M) $5,085 $5,125 Y/Y Core Revenue Growth (2) 2.7% 4.1% Y/Y Core Revenue Growth (2) 4.0%